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Abstract 
Sialic acid sugars on the surface of cancer cells have emerged as potent immune modulators that 
contribute to the immunosuppressive microenvironment and tumor immune evasion. However, the 
mechanisms by which these sugars modulate anti-tumor immunity as well as therapeutic strategies 
directed against them are limited. Here we report that intratumoral injections with a sialic acid mimetic 
Ac53FaxNeu5Ac blocks tumor sialic acid expression in vivo and suppresses tumor growth in multiple 
tumor models. Sialic acid blockade had a major impact on the immune cell composition of the tumor, 
enhancing tumor-infiltrating natural killer cell and CD8+ T cell numbers while reducing regulatory T cell 
and myeloid regulatory cell numbers. Sialic acid blockade enhanced cytotoxic CD8+ T cell-mediated 
killing of tumor cells in part by facilitating antigen specific T cell-tumor cell clustering. Sialic acid 
blockade also synergized with adoptive transfer of tumor-specific CD8+ T cells in vivo and enhanced CpG 
immune adjuvant therapy by increasing dendritic cell activation and subsequent CD8+ T cell responses. 
Collectively, these data emphasize the crucial role of sialic acids in tumor immune evasion and provide 
proof of concept that sialic acid blockade creates an immune-permissive tumor microenvironment for 
CD8+ T cell-mediated tumor immunity, either as single treatment or in combination with other immune-
based intervention strategies. 
 
Introduction 
Altered glycosylation is a hallmark of virtually all cancer cells from different origins, and several aspects 
of tumor growth and progression are mediated by tumor-associated glycans (1,2). One of the most 
remarkable change in cancer glycosylation is the aberrant expression of sialic acid-carrying glycans 
(sialoglycans) (3). Sialic acids are a family of negatively charged, nine-carbon sugar molecules that often 
terminate the glycans of cell surface glycoproteins and glycolipids. Human cancer cells cover their 
membrane with a dense layer of sialoglycans and also express unique sialoglycans on their surface (e.g. 
SLea/x, STn, GM2/3, GD2/3 or SSEA-4) (4-6). Tumor sialoglycans facilitate cancer cell migration and 
metastasis formation and moreover tumor sialoglycans emerge as potent immune modulators that promote 
tumor immune evasion (3,7-10). Already in the 1960s, it has been proposed that the dense layer of sialic 
acids surrounding tumor cells protects them from recognition and eradication by the immune system, and 
even clinical trials were performed using irradiated cancer cells treated with bacterial sialidase as vaccine 
in patients with cancer. At that time, however, contradicting data and the lack of effective glycotools to 
provide further mechanistic insight dampened the enthusiasm of the scientific community (11-13). Recent 
developments in glycoengineering have revitalized research on the potential role of sialic acids in the anti-
tumor immune response. These studies in human and animal models have shown that tumor sialic acids 
negatively influence immune cell function by interacting with the immune inhibitory sialic acid-binding 
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immunoglobulin-like lectin (Siglec) family (14-19). Tumor sialic acid-Siglec interactions, therefore are 
believed to modulate immune cell function and hinder anti-tumor immunity (7,8,10,20-22). 
Approaches to interfere with sialoglycan expression in cancer in vivo are, however, still limited and barely 
tested in preclinical tumor models. So far, mainly bacterial sialidases or tumor cells with genetically 
silenced sialic acid expression were used to study the effects of tumor sialic acids (9,18,23). While these 
approaches are useful to study some aspects of tumor sialylation, they are difficult to apply in a 
therapeutic setting to interfere with sialic acid expression in established tumors. Pharmacological 
inhibition of sialic acid expression in tumors in vivo, however, has not been feasible so far. Our group has 
reported that a fluorinated sialic acid mimetic, Ac53FaxNeu5Ac, originally reported by Rillahan et al., 
potently blocked sialic acid expression in various human and mouse cancer cell lines (24-26). 
Ac53FaxNeu5Ac blocks sialic expression directly by the inhibition of sialyltransferases, the enzymes that 
incorporate sialic acids into glycans and indirectly by stopping the production of natural sialic acids in the 
cell (24,27). Previously, we found that blocking sialylation with Ac53FaxNeu5Ac impaired cancer cell 
adhesion and migration in vitro and prevented metastasis formation in vivo (26,28). Here we explored the 
potential of Ac53FaxNeu5Ac to block sialic acid expression in the tumor mass and investigated the 
consequences thereof on the tumor microenvironment and anti-tumor immunity. 
Our data demonstrate that intratumoral injections of Ac53FaxNeu5Ac blocked sialylation in tumors in vivo 
and suppressed tumor growth in different murine tumor models. Mechanistic studies revealed dominant 
effects on the tumor microenvironment and dependence on CD8
+
 T cells. Sialic acid blockade potentiated 
cellular immunotherapy as well as CpG immunotherapy through enhanced maturation of dendritic cells in 
the tumor microenvironment favoring the induction of CD8+ T cells. These data emphasize the important 
role of sialic acids in tumor immune evasion and identify Ac53FaxNeu5Ac as potential prototype 
therapeutic molecule for the use in cancer immunotherapy.  
 
Materials and Methods 
Mice 
Female C57BL/6JRccHsd WT mice (Harlan Laboratories) 8 to 10 weeks old at the beginning of the 
experiments were housed in the local Central Animal Laboratory. OT-I mice that produce CD8+ T cells 
with a transgenic T cell receptor specific for the chicken ovalbumin (OVA) epitope SIINFEKL (OVA257-
264) presented on MHC I H-2k
b and the congenic marker CD45.1+ were bred in the Central Animal 
Laboratory. Animals were housed under specific pathogen-free conditions and ad libitum access to food 
and water. All animal experiments were authorized by the local animal ethics committee and carried out in 
accordance with their guidelines. 
Reagents and Antibodies 
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Ac53FaxNeu5Ac and Ac5Neu5Ac were synthesized as described before (24-26). Carbo-free blocking 
solution, biotinylated lectins MALII, SNA-I and PNA were purchased from Vector Laboratories Inc., 
streptavidin-PE from BD Pharmingen and eFluor 780 viability dye and anti-CD11b-biotin (M1/70) from 
eBioscience, Inc. CD8 (2.43), CD4 (GK1.5), NK1.1 (PK136) and Gr-1 (RB6.8C5) depleting mAbs were 
produced by culturing hybridomas in IMDM with 1 % FBS. Clodronate liposomes were purchased from 
Liposoma B.V., OVA257-264 (SIINFEKL) was purchased from AnaSpec Inc. and CpG ODN 1826 from 
InvivoGen. Clostridium perfringens sialidase, β-galactosidase and DAPI were purchased from Sigma-
Aldrich. CFSE, PBSE and AF488-conjugated streptavidin were obtained from Thermo Fisher and anti-
CD16/CD32 (2.42G), anti-CD45.2-biotin (104) and anti-CD161/NK1.1-PE (PK136) from BD 
Pharmingen. Anti-CD8α-AF700 (53-6.7) was purchased from EXBIO and anti-CD4-PerCP (RM4-5), 
anti-CD11c-APC (N418), anti-CD11b-AF700 (M1/70), anti-CD45R/B220-PerCp (RA3-6B2), anti-H-
2Kb/H-2Db-PE (28-8-6), and anti-CD8α -biotin (53-6.7) from BioLegend. Anti-CD25-APC (PC61.5), anti-
FoxP3-PE-Cy7 (FJK-16s), anti-Mult-1-PE (5D10) and anti-CD274/PD-L1-PE (MIH5) were obtained 
from eBioscience and anti-Rae-1-APC (FAB17582A) from R&D Systems. Anti-biotin-Cy3 was obtained 
from Jackson ImmunoResearch. 
  
Cell culture and titration of Ac53FaxNeu5Ac 
B16-F10WT melanoma cells were obtained from and authenticated by ATCC (CRL-6475) and cultured in 
MEM (Gibco) containing 5 % FBS (Greiner Bio-one), 1 % MEM non-essential amino acids (Gibco), 0.15 
% sodium bicarbonate (Gibco), 1 mM sodium pyruvate (Gibco), 1.5 % MEM vitamins (Gibco), 1 % 
antibiotic-antimycotic solution (PAA). B16-F10OVA cells (clone MO5) were kindly provided by Dr. 
Kenneth Rock and cultured in B16-F10WT medium supplemented with 200 µg/ml geneticin (Gibco) and 
Hygromycin B (Merck) (29). No full authentication of the B16-F10OVA cells was carried out by the 
authors, but the expression of OVA, TRP-2, TRP-2, MHC I and other molecules was validated. The 
9464D neuroblastoma cell line (kindly provided by R. Orentas, Department of Pediatrics, Medical College 
of Wisconsin, WI, USA) was authenticated last by the authors in 2013 by qPCR analysis of 
neuroblastoma-specific genes. 9464D cells were cultured in DMEM Glutamax (Gibco) with 10 % FBS, 1 
% non-essential amino acids, 20 µM 2-mercaptoethanol (Sigma-Aldrich) and 1 % antibiotic-antimycotic 
solution (30,31). All cell lines were initially grown and multiple aliquots were cryopreserved. The cells 
were used within 3 months after resuscitation and regularly tested for mycoplasma using a mycoplasma 
detection kit (Lonza). To compare the effect of Ac53FaxNeu5Ac on sialic acid expression between B16-
F10WT and B16-F10OVA cells, both cell lines were incubated for 3 days with 100 µM Ac53FaxNeu5Ac. To 
determine the effective dose of Ac53FaxNeu5Ac in 9464D cells, they were incubated for 3 days with 0-500 
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µM sialic acid mimetic. Sialylation was quantified by flow cytometry using lectins as described below. 
All cells were incubated in a humidified CO2 incubator at 37 °C.  
 
In vivo tumor experiments 
Following reconstitution from liquid nitrogen, tumor cell lines were cultured in T75 flasks (Corning), 
passaged twice and grown to 60-70 % confluency. Cells were collected in 1x PBS at a concentration of 
0.5 x 106 cells/ml (B16-F10WT), 1 x 106 cells/ml (B16-F10OVA) or 10 x 106 cells/ml (9464D) and 100 μl of 
the cell suspension was injected subcutaneously into the right flank of the mice under isoflurane 
anesthesia. Tumor size was examined every 2-3 days and tumor volumes were calculated with the formula 
((A × B2) × 0.4), in which A is the largest and B is the shortest tumor dimension. Mice were sacrificed 
when the tumor volume exceeded 1800 mm3. Ac53FaxNeu5Ac and Ac5Neu5Ac were dissolved in 1x PBS, 
and on day 10 when a palpable tumor mass was formed 50 µl of 1x PBS containing 10, 20 or 30 mg/kg 
sialic acid mimetic were injected into the tumor mass thrice per week. Optional, CpG was injected into the 
tumor mass on day 14 and 21 post-inoculation. Naïve mice were injected subcutaneously three times per 
week with sialic acid mimetic for two weeks. PBS only injections were used as control. For rechallenge 
experiments in the B16-F10OVA model, 30,000 B16-F10OVA cells were injected subcutaneously into the left 
femur of mice with remission after the initial tumor challenge or naïve, age-matched control mice and 
tumor growth was monitored in time. For the depletion of CD4+, CD8+, NK1.1+ or Gr-1+ cells in vivo 300 
μg depleting mAbs or isotype control antibodies were injected intraperitoneally either two days before 
tumor inoculation or on day 6, 8 and day 20 after tumor inoculation, respectively. 1 mg/mouse clodronate 
liposomes was injected intraperitoneally on day 8 post inoculation and from day 10 onwards, mice 
received 0.25 mg injections twice per week until the end of the experiment to maintain depletion. 
 
Preparation of single cell suspensions  
Mice were sacrificed by cervical dislocation and the tumor, spleen, draining and non-draining lymph 
nodes (superficial inguinal) were isolated. Tumors and spleens were mashed through a 100 µm nylon cell 
strainer and collected in 1x PBS and red blood cells were lysed by incubating the suspension for 1 minute 
in ice-cold ACK lysis buffer (150 mM NH4Cl, 10 mM KHCO3 and 0.1 mM Na2-EDTA, pH 7.2). Lymph 
nodes were comminuted between glass slides and single cells were harvested in 1x PBS.  
 
Intra-/extracellular cell staining and flow cytometry analysis 
For extracellular staining with biotinylated lectins, the cells were washed with 1x carbo-free blocking 
solution and incubated for 45 minutes at 4 °C with MALII (5 µg/ml), SNA-I (1 µg/ml) or PNA (5 µg/ml) 
in 1x carbo-free blocking solution containing 1 mM CaCl2+ and 1 mM MgCl2+. Next, cells were washed 
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with 1x carbo-free blocking solution, incubated for 20 minutes at 4 °C with streptavidin-PE conjugate, 
washed again and resuspended in PBA (1x PBS, 1 % BSA, and 0.02 % sodium azide) for flow cytometry 
analysis. For extracellular antibody staining, cells were first incubated 10 minutes at 4 °C with PBA 
containing Fc receptor blocking antibody (2.42G), then washed with PBA and incubated for 20 minutes at 
4 °C with fluorescent antibodies. After extensive washing, the cells were resuspended in PBA for flow 
cytometry analysis or further used for intracellular staining. For intracellular stainings, a cell fixation and 
permeabilization kit (BD) was used following the manufacturer’s instructions. Briefly, cells were 
incubated for 20 minutes with 1x fix/perm solution at 4 °C and washed with perm/wash buffer. Next, cells 
were incubated overnight with antibody in perm/wash buffer at 4 °C, washed with perm/wash buffer and 
resuspended in PBA for flow cytometry analysis. Cells were measured using a CyAn ADP flow cytometer 
(Beckman Coulter) and data were analyzed using FlowJo software (Tree Star Inc.). 
 
Urine and blood collection and determination of albuminuria and serum urea 
Naïve mice were subcutaneously injected three times a week for two weeks with PBS, 10, 20 or 30 mg/kg 
Ac53FaxNeu5Ac. At several time points, urine of the mice was collected and pooled per time point and 
treatment group and blood was collected via the tail vein into MiniCollect tubes (Greiner Bio-one). To 
obtain serum, the tubes were centrifuged for 10 minutes, 12,000 rpm, at room temperature. Albumin 
concentrations were measured by radial immunodiffusion (Mancini). Urinary creatinine and serum urea 
levels were determined as described earlier (32). 
 
Immunohistochemistry 
To assess the effect of sialic acid blockade on the tumor microenvironment, B16-F10WT tumors injected 
for two weeks with PBS or 10 mg/kg Ac53FaxNeu5Ac were isolated on day 24 post inoculation and snap 
frozen in liquid nitrogen. To investigate the effects of Ac53FaxNeu5Ac injections on the kidneys, naïve 
mice received subcutaneous injections with PBS, 10, 20 or 30 mg/kg Ac53FaxNeu5Ac three times per 
week for two weeks. Two or four weeks after starting the treatment, kidneys were collected and snap 
frozen in liquid nitrogen. Immunohistochemical analysis of the tumors and kidneys was performed as 
described previously (33). Briefly, frozen tumor sections (5 µm) and renal sections (2 µm) were fixed in 
ice-cold acetone for 10 minutes and incubated with the biotinylated lectins MALII, SNA-I or PNA diluted 
in PBA for 45-60 minutes. For antibody stainings, the sections were blocked for 30 minutes with 2 % 
donkey serum and incubated for 60 minutes with anti-CD8α-biotin or anti-CD11b-biotin antibodies 
followed by 10 minutes staining with DAPI in PBS. Biotinylated lectins and antibodies were detected with 
AF488-streptavidin or anti-biotin-Cy3 antibodies. Images were acquired with a Zeiss Axio Imager M1 
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fluorescence microscope. Fluorescence intensity was evaluated semi-quantitatively from 0 (no staining) to 
10 (100 % maximum intensity) on blinded sections.  
 
In vitro CD8+ OT-I activation  
To obtain activated CD8+ OT-I cells, single cell suspensions prepared from OT-I spleens were cultured for 
4 days in the presence of 0.75 µg/ml OVA257-264 peptide in RPMI-1640 medium (Life Technologies) 
supplemented with 10 % FBS (Greiner Bio-one), 2 mM glutamine (Lonza) and 1x antibiotic-antimycotic 
solution (100 units/mL of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL Fungizone) (Life 
Technologies). On day 3, 5 ng/ml recombinant mouse IL-2 (ImmunoTools) was added to the culture. 
Following activation, CD8+ OT-I cells were purified using a CD8a+ T Cell isolation kit according to the 
manufacturer’s protocol (Miltenyi Biotec).  
 
OT-I killing and clustering assay  
For in vitro killing assays, B16-F10WT, B16-F10OVA, 9464DWT, or 9464DOVA cells were cultured for three 
days with PBS, 100 µM Ac5Neu5Ac, 100 µM (B16-F10) or 250 µM Ac53FaxNeu5Ac. Alternatively, B16-
F10 cells were treated for 60 minutes at 37 °C with 250 mU/ml sialidase, 1 U/ml β-galactosidase or PNA 
lectin was added to the culture. The cells were extensively washed with 1x PBS and 30,000 cells were 
seeded into 96-wells flat bottom wells (Costar). Cells were allowed to adhere for two hours before 
purified, activated OT-I CD8
+
 T cells were added in different effector-to-target ratios (0.1:1, 0.25:1, 0.5:1, 
1:1, 2:1). After 16 hours of co-culture, images were taken and numbers of live tumor cells and CD8+ 
CD90.1+ OT-I T cells were quantified using flow cytometry. Percentage killing was calculated by 
normalizing the number of viable tumor cells in the co-cultures to control cultures without effector T cells. 
To determine cluster formation between tumor cells and T cells, B16-F10WT or B16-F10OVA cells treated 
with control or 100 µM Ac53FaxNeu5Ac for 3 days were labeled with 3 µM PBSE and activated CD8
+ 
OT-I cells were labeled with 0.5 µM CFSE following the manufacturer’s instructions. B16-F10 cells and 
OT-I cells were incubated together in a 1 : 2 ratio in medium for 2 hours at 37 °C rotating, fixed with PFA 
and the number of PBSE+/CFSE+ clusters was determined by flow cytometry.  
 
Adoptive OT-I cell transfer 
For adoptive transfer experiments, 10 x 106 purified OT-I cells were injected intraperitoneally on day 15 
following inoculation. Tumor growth was monitored or tumors were isolated two days after adoptive 
transfer to assess OT-I CD8+ T cell infiltration and activation marker expression by flow cytometry. For 
the latter experiment, OT-I CD8+ T cells were labeled with 3 µM CFSE prior to adoptive transfer 
following the manufacturer’s instructions. 
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qPCR 
Expression of Siglec family members on activated OT-I CD8+ T cells and total splenocytes was 
determined by qPCR. RNA was isolated from OT-I CD8+ T cells or splenocytes using a RNA isolation kit 
(Zymo Research) following the manufacturer’s instructions. RNA samples were treated in-column with 
DNase I and analyzed by spectrophotometry. Next, cDNA was synthesized using random hexamers and 
Moloney murine leukemia virus reverse transcriptase (Invitrogen). Siglec expression was determined with 
a CFX96 system (Bio-Rad) using SYBR Green reaction mix (Sigma-Aldrich). Data were calculated as 
relative expression to the housekeeping gene Gapdh. Primer sequences were derived from the Harvard 
Primer Bank.  
 
Statistical analysis  
Significance between two groups was calculated using a student’s t-test. Comparisons between multiple 
groups were made using one-way analysis of variance (ANOVA) followed by Bonferroni’s correction. 
Kaplan-Meier survival curves were analyzed with a log-rank test using Prism 5 software (GraphPad Inc.) 
and p-values <0.05 were considered significant (p<0.05 *, p<0.01 **, p<0.001 ***).  
 
Results 
Intratumoral Ac53FaxNeu5Ac injections suppress tumor growth. 
The sialic acid mimetic Ac53FaxNeu5Ac specifically blocks sialic acid expression in human and mouse 
cell lines in vitro without affecting cell viability or proliferation (25,26). In vitro pre-treatment of mouse 
B16-F10WT melanoma cells with this sialic acid mimetic delayed their outgrowth in vivo following 
subcutaneous injection, and moreover prevented metastatic spread (26,28). These data prompted us to 
investigate the effect of intratumoral administration of Ac53FaxNeu5Ac on tumor growth in different 
mouse tumor models. Mice bearing palpable B16-F10WT tumors were injected with 10 or 30 mg/kg 
Ac53FaxNeu5Ac into the tumor mass three times a week for four weeks (Fig. 1A). This treatment schedule 
was based on our previous observation that the blocking effect of Ac53FaxNeu5Ac lasted for 2 (α2,6-
linked sialic acids) to 4 days (α2,3-linked sialic acids) in B16-F10WT cells after inhibitor removal (26). 
Injections with PBS and 10 or 30 mg/kg peracetylated non-blocking sialic acid (Ac5Neu5Ac) were used as 
controls. B16-F10WT tumors injected with PBS grew rapidly, resulting in a median survival time of 24 
days (Fig. 1B, C). While control injections with Ac5Neu5Ac sialic acid had no effect on tumor growth, 
Ac53FaxNeu5Ac injections significantly suppressed tumor growth in this stringent tumor model. In a dose-
dependent manner, treatment with the sialic acid-blocking mimetic increased median survival times from 
24 days to 36 (10 mg/kg) and 47 days (30 mg/kg), respectively (Fig. 1B, C and Fig. S1).  
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Next, sialic acid blockade therapy with Ac53FaxNeu5Ac was tested in the related, more immunogenic 
ovalbumin-expressing B16-F10OVA model and an unrelated 9464D neuroblastoma model. In vitro, B16-
F10OVA cells had a comparable sensitivity to Ac53FaxNeu5Ac (100 µM) as B16-F10
WT cells, whereas a 
higher dose (> 250 µM) was required for 9464D cells (Fig. S2). In the 9464D model, injections of 10 
mg/kg had little effect on tumor growth, whereas 20 mg/kg injections significantly increased the median 
survival from 40 days to 58 days (Fig. 1D). In the B16-F10OVA model, 10 mg/kg Ac53FaxNeu5Ac 
injections strongly reduced tumor growth and resulted in complete remission in about half of the mice 
(Fig. 1E, F). These mice remained tumor-free for over 120 days post-inoculation. Upon rechallenge of the 
surviving mice with B16-F10OVA cells, about 60 % of the mice were protected from tumor outgrowth (Fig. 
1G). The protection upon re-challenge is suggestive for a curative immune response induced by the 
Ac53FaxNeu5Ac injections. Furthermore, these data show that sialic acid blockade suppresses tumor 
growth in poorly immunogenic melanoma as well as neuroblastoma models and results in tumor 
regression in the more immunogenic B16-F10OVA model.  
In the tumor growth experiments described above, no adverse effects or weight changes were observed 
upon repeated intratumoral injections with the 10 mg/kg dose. In mice receiving repeated injections with 
20 and 30 mg/kg Ac53FaxNeu5Ac, we detected abdominal fluid accumulation, an increase in weight and 
reduced kidney function around two weeks after treatment start (Fig. S3). No effect on kidney function 
was, however, observed in mice injected with 10 mg/kg Ac53FaxNeu5Ac, therefore this dose was used for 
all subsequent experiments. 
 
Ac53FaxNeu5Ac blocks sialic acid expression in the tumor mass. 
Next, we assessed the effect of intratumoral injections with 10 mg/kg Ac53FaxNeu5Ac or control 
Ac5Neu5Ac on the sialylation of tumor cells as well as tumor-infiltrating lymphocytes. After two weeks of 
injections, B16-F10WT tumors were isolated and analyzed by flow cytometry (Fig. S4). Tumor cells were 
defined as leukocyte marker CD45.2-negative cells and immune cells as CD45.2-positive cells. 
Ac53FaxNeu5Ac injections reduced α2,3-sialic acid expression on tumor cells by 60 % and α2,6-sialic acid 
expression by 50 % compared to control (Fig. 2A-C). Accordingly, exposure of galactose residues was 
detected with PNA lectin (Fig. 2A, D). A clear reduction in sialic acid expression and exposure of 
galactose residues was also observed on tumor sections (Fig. 2E-G). Interestingly, in tumors injected with 
PBS or Ac5Neu5Ac, more tumor cells than immune cells were present (CD45
+/CD45- ratio 0.32-0.43), but 
Ac53FaxNeu5Ac injections significantly increased the immune cell to tumor cell ratio (3.1) (Fig. 2H, Fig. 
S4). While Ac53FaxNeu5Ac treatment strongly reduced sialylation of tumor cells, also CD45.2
+ tumor-
infiltrating lymphocytes showed reduced sialylation (20 %) (Fig. 2I-K). Noteworthy, no significant 
changes in the sialylation of cells in the tumor-draining lymph node, non-draining lymph nodes or spleen 
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were detected (Fig. S5). Altogether these data show that intratumoral injections with Ac53FaxNeu5Ac 
block sialic acid expression locally in the tumor mass, but not systemically. Moreover, these data indicate 
that tumor cells have a higher sensitivity to the sialic acid mimetics compared to infiltrating immune cells.  
 
Sialic acid blockade alters the tumor immune cell composition. 
Sialic acid blockade suppressed tumor growth and even resulted in complete remission and protection 
from a subsequent rechallenge in the B16-F10OVA model. These findings, together with the observed high 
tumor-infiltrating lymphocyte-to-tumor cell ratio after Ac53FaxNeu5Ac treatment indicate that the loss of 
sialic acids affects tumor immunity. Therefore, we assessed the immune cell composition of B16-F10WT 
tumors treated for two weeks with the sialic acid-blocking mimetic. Compared to PBS and Ac5Neu5Ac-
treated tumors, Ac53FaxNeu5Ac treatment increased the percentage of NK cells, CD8
+ T cells and CD4+ T 
cells within the viable, tumor-infiltrating lymphocyte population (Fig. 3A-D, Fig. 3E-G, Fig. S6). In 
addition, the number of regulatory T cells was significantly reduced compared to control-injected tumors 
(Fig. 3D, H). Noteworthy, while the percentages of tumor-infiltrating B cells and dendritic cells remained 
unaltered between the treatment groups, Ac53FaxNeu5Ac injections strongly reduced the percentage of 
myeloid regulatory cells in the tumor (Fig. 3I-K, Fig. S6). Similar results were obtained when performing 
the same experiment in the 9464D model. The immune cell composition in the (non-)draining lymph 
nodes and spleen remained unaltered (Fig. S6, Fig. S7). These results demonstrate that Ac53FaxNeu5Ac 
injections alter the tumor microenvironment composition, resulting in increased numbers of effector 
immune cells while lowering regulatory T cell and myeloid cell numbers. Furthermore, these results 
indicate that sialic acid blockade converts the immune suppressive tumor microenvironment into a more 
immune permissive one.  
 
Tumor growth suppression upon sialic acid blockade is mediated by CD8+ T cells. 
The findings so far suggest that sialic acid blockade counteracts the immune suppressive tumor 
microenvironment and influences anti-tumor immunity. Therefore, we investigated if the growth 
inhibitory effect of Ac53FaxNeu5Ac on established tumors was mediated by effector immune cells. B16-
F10WT tumor-bearing mice were depleted from NK cells, CD4+ T cells or CD8+ T cells using monoclonal 
antibodies and treated as described in Fig. 4A. Successful depletion of NK cells and T cells from the mice 
was confirmed (Fig. 4B-D). In line with the previous experiments, intratumoral Ac53FaxNeu5Ac injections 
hampered tumor growth in mice receiving isotype antibodies and increased median survival from 18.5 
days to 39.5 days (Fig. 4E). Depletion of neither NK cells nor CD4+ T cells had a significant effect on 
Ac53FaxNeu5Ac-mediated tumor growth suppression (Fig. 4E). Remarkably, depletion of CD8
+ T cells 
from mice largely abolished the anti-tumor effect of Ac53FaxNeu5Ac resulting in a median survival time 
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of only 25 days (Fig. 4F). Of note, depletion of NK cells and CD8+ T cells prior to tumor cell inoculation 
both facilitated tumor take and abrogated the anti-tumor effect of Ac53FaxNeu5Ac (Fig. S8). As expected, 
depletion of macrophages and myeloid cells with clodronate liposomes or anti-Gr-1 antibodies in the B16-
F10WT tumor model already significantly inhibited tumor growth by itself (34,35). The finding that 
addition of the fluorinated sialic acid mimetic to this treatment further delayed tumor growth and 
significantly prolonged survival supports a role of the inhibitor beyond myeloid cells. (Fig. S9). 
Altogether, these data suggest that the growth suppressive effects of Ac53FaxNeu5Ac on established 
tumors is largely mediated by CD8+ T cells.  
 
Sialic acid blockade promotes tumor eradication by CD8+ T cells. 
To further elucidate how CD8+ T cells mediate the anti-tumor effects of Ac53FaxNeu5Ac, we assessed the 
cytotoxic effects of OVA-specific OT-I CD8+ T cells on sialic acid competent or deficient B16-F10OVA 
cells in vitro. Sialic acid blockade strongly enhanced the eradication of B16-F10OVA cells by activated OT-
I CD8+ T cells already at low effector to target ratios (Fig. 5A, B). This effect was also observed with 
sialidase-treated B16-F10OVA cells and killing assays using 9464DOVA cells as targets (Fig. 5B, Fig. S10). 
B16-F10WT and 9464DWT cells were not sensitive to OT-I CD8+ T cell cytotoxicity, irrespective of their 
sialylation status. Next, we investigated if the exposure of galactose residues upon sialic acid blockade 
mediated the enhanced T cell killing. Galactose residues on B16-F10 cells were either blocked with PNA 
lectin or enzymatically removed. Galactosidase treatment did not alter the enhanced killing of desialylated 
B16-F10OVA compared to control cells and incubation with PNA only slightly reduced the difference in 
killing (Fig. S10). Furthermore, activated OT-I CD8+ T cells expressed no immunomodulatory Siglec 
receptors that potentially could recognize tumor sialic acids (Fig. S10) and treatment of B16-F10OVA cells 
with Ac53FaxNeu5Ac had no effect on MHC I expression or other molecules involved in effector immune 
cell interactions (PD-L1, Rae1, Mult-1) (Fig. S11). Moreover, the concentration of Ac53FaxNeu5Ac used 
in B16-F10 cells had no effect on OT-I CD8+ T cell sialylation (Fig. S11). Hence, the increase in OT-I 
CD8+ T cell killing was most likely not mediated by Siglec receptors on these cells and only to a minor 
extent by exposure of penultimate galactose.  
Next we investigated if sialic acid blockade influenced the interaction of B16-F10OVA cells with OT-I 
CD8+ T cells. In tumor cell-T cell clustering assays, B16-F10OVA cells treated with Ac53FaxNeu5Ac 
formed significantly more clusters (6 %) compared to control cells (3.9 %) (Fig. 5C, D). This effect was 
antigen-specific as no clear increase in cluster formation was observed in B16-F10WT cells. These data 
indicate that sialic acid blockade increases killing of B16-F10 cells by CD8+ T cells in an antigen-specific 
manner, possibly by facilitating cancer cell-T cell interactions.  
 
on July 27, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 27, 2018; DOI: 10.1158/0008-5472.CAN-17-3376 
Sialic Acid Blockade Boosts Anti-Tumor Immunity 
12 
 
Based on these results we tested if sialic acid blockade enhanced OT-I CD8+ T cell-mediated tumor killing 
in vivo. Purified, activated OT-I CD8+ T cells were adoptively transferred into mice bearing subcutaneous 
B16-F10OVA tumors that were treated with PBS or Ac53FaxNeu5Ac (Fig. 6A, Fig. S11). Sialic acid 
blockade significantly increased OT-I CD8+ T cell infiltration in the tumor mass (two fold) (Fig. 6B). OT-
I CD8+ T cells isolated from tumors treated with Ac53FaxNeu5Ac compared to control displayed a more 
cytotoxic phenotype with higher expression of the activation markers CD44 and CD69 and the 
degranulation marker CD107a (Fig. 6C-E). These results suggest that sialic acid blockade renders tumor 
cells vulnerable to cytotoxic CD8+ T cell killing. Accordingly, Ac53FaxNeu5Ac injections enhanced 
rejection of established B16-F10OVA tumors by adoptively transferred OT-I CD8+ T cells. Without sialic 
acid blockade therapy, adoptive OT-I CD8+ T cell transfer enhanced median survival time from 20 days to 
28 days compared to mice without T cell transfer (Fig. 6F, G). In combination with sialic acid blockade, 
OT-I CD8+ T cell transfer strongly increased the median survival time of the mice and resulted in 
complete remission in the majority of the mice (> 60 %) (Fig. 6F, G). Altogether, these data imply that 
sialic acids protect tumor cells from killing by CD8+ effector T cells and that sialic acid blockade therefore 
facilitates T cell-mediated tumor immunity. 
 
Sialic acid blockade synergizes with CpG immunotherapy. 
Based on our findings that sialic acid blockade facilitates CD8+ T cell-mediated tumor immunity we 
hypothesized that adjuvants able to induce CD8
+
 T cell responses could potentially strengthen the 
antitumor effect of sialic acid blockade. The Toll-like receptor 9 (TLR9) ligand CpG induces functional 
maturation of dendritic cells, the key antigen-presenting cells of the immune system capable of activating 
tumor-specific CD8+ T cells (36). Therefore, Ac53FaxNeu5Ac treatment was combined with CpG adjuvant 
injections in the stringent B16-F10WT model (Fig. 7A). CpG injections alone had no significant effect on 
tumor growth, but the combination of CpG with Ac53FaxNeu5Ac significantly delayed tumor growth and 
increased the median survival time from 24 days (Ac53FaxNeu5Ac alone) to 35 days (Fig. 7B, C). CpG 
has been shown to induce dendritic cell maturation in the tumor (36,37). Accordingly, we found that CpG 
injections enhanced maturation of CD11c+ dendritic cells in the tumor as shown by the upregulation of the 
costimulatory molecules CD80 and CD86 (Fig. 7D-F). Interestingly, Ac53FaxNeu5Ac injections alone also 
increased CD80 and CD86 upregulation, although to lesser extent than CpG. Strikingly, combining both 
compounds strongly induced dendritic cell maturation in the tumor. This strong upregulation of CD80 and 
CD86 after combination treatment was also observed in dendritic cells in the tumor-draining lymph node, 
but not in the non-draining lymph nodes or the spleen (Fig. S12). In line with the enhanced dendritic cell 
maturation in the tumor and tumor-draining lymph node, high numbers of activated CD8+ CD107a+ 
cytotoxic T cells were detected in tumors after CpG and Ac53FaxNeu5Ac combination treatment (Fig. 7G-
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J, Fig. S13). These data indicate that sialic acid blockade together with the CD8+ T cell promoting activity 
of CpG induces highly potent anti-tumor immune responses and shows the potential potency of 
combinatorial strategies with sialic acid blockade. 
 
Discussion 
Aberrant sialic acid expression has been associated with multiple aspects of tumor growth and 
progression. Yet, pharmacological inhibition of sialic acid expression in tumors in vivo has not been 
feasible so far. The therapeutic potential of sialic acid inhibition in cancer therefore remains unexplored. 
In this study, we investigated the use of the fluorinated sialic acid mimetic Ac53FaxNeu5Ac to block sialic 
acid expression in established tumors and studied its effects on tumor growth, the tumor 
microenvironment and tumor immunity. First, we found that repeated intratumoral injections with the 
sialic acid mimetic were well tolerated and blocked sialic acid expression locally in tumor cells. Sialic 
acid blockade suppressed B16-F10WT melanoma and 9464D neuroblastoma growth and even had a 
curative effect in the immunogenic B16-F10OVA tumor model. Second, sialic acid blockade changed the 
immune suppressive tumor microenvironment into a more permissive one with higher numbers of 
activated effector immune cells and significantly less regulatory T cells and myeloid regulatory cells. 
Third, we found that anti-tumor effects of Ac53FaxNeu5Ac injections were largely mediated by CD8
+ 
effector T cells. Sialic acid blockade rendered tumor cells highly vulnerable to killing by cytotoxic T cells 
in vitro and in vivo following adoptive transfer. These data demonstrate that sialic acid blockade enhances 
the efficacy of cellular immunotherapy. In addition, Ac53FaxNeu5Ac injections also potentiated the 
activation of dendritic cells with CpG in vivo. This combination therapy induced a robust CD8+ T cell 
response in mice resulting in strong growth suppression of poorly immunogenic B16-F10WT tumors.  
Due to recent advances in carbohydrate chemistry, glycomimetics like Ac53FaxNeu5Ac that can be 
synthesized in large amounts and with high purity now become available for testing in preclinical models. 
In vitro, Ac53FaxNeu5Ac potently blocks sialic acid expression without affecting other glycosylation 
pathways and even high concentrations and long-term exposure of cancer cells and primary cells with 
Ac53FaxNeu5Ac showed no effect on cell viability or proliferation (24,26,38). Accordingly, repeated 
intratumoral injections with 10 mg/kg sialic acid mimetic were generally well-tolerated, although 
prolonged exposure to a higher dose resulted in nephrotoxicity. The intratumoral injections blocked sialic 
acid expression efficiently in tumor cells, but also a significant reduction in sialic acid expression was 
found on immune cells. No effect on systemic sialylation was observed after injections with 10 mg/kg 
Ac53FaxNeu5Ac. Probably, due to the intratumoral administration, a large part of the mimetic is retained in 
the tumor mass, thereby limiting systemic exposure. Furthermore, our data indicate that B16-F10 cells are 
more sensitive to sialic acid blockade with Ac53FaxNeu5Ac compared to the tumor-infiltrating immune 
on July 27, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 27, 2018; DOI: 10.1158/0008-5472.CAN-17-3376 
Sialic Acid Blockade Boosts Anti-Tumor Immunity 
14 
 
cells. Therefore, blocked sialic acid expression in tumor cells is most likely responsible for the observed 
effects in the tumor microenvironment, although diminished sialic acid expression on the local immune 
cells may contribute as well. In line with these findings, Wu and colleagues showed that tumor cells have 
a higher preference to take up sialic acids compared to other tissues (39,40). We found, however, also a 
difference in the sensitivity of B16-F10 cells and 9464D cells for Ac53FaxNeu5Ac in vitro and in vivo. 
While 10 mg/kg sialic acid mimetics injections were sufficient to block sialic acid expression in the B16-
F10 model, 20 mg/kg were needed to reduce sialic acid expression and tumor growth in the 9464D model. 
This difference in sensitivity between the two cell types can most likely be explained by differences in 
uptake of the inhibitor, levels of competing endogenous sialic acid concentrations or sialyltransferase 
expression levels.  
Repeated injections with 10 mg/kg Ac53FaxNeu5Ac had no effect on systemic sialylation and showed no 
adverse effects, but injections with a higher dose for several weeks caused a reduction in sialic acid 
expression in the kidney and resulted in kidney failure and edema formation. Most likely, Ac53FaxNeu5Ac 
that is not retained in the tumor can accumulate in the kidney resulting in reduced sialic acid expression in 
the glomeruli and disturbed glomerular filtration. These results confirm recent findings by Macauley and 
colleagues who showed that intravenous administration of 300 mg/kg Ac53FaxNeu5Ac leads to kidney 
failure and a study by Galeano and colleagues who showed that a genetic defect in sialic acid synthesis 
results in defective glomeruli and proteinuria (41,42). Except for the kidney phenotype we could not 
observe any other adverse effects following Ac53FaxNeu5Ac or Ac5Neu5Ac injections. Even mice 
undergoing remission after treatment of the B16-F10OVA tumors with the sialic acid mimetic that were 
monitored for several months showed no pathological features. These data strongly suggest that the 
observed adverse effect on the kidneys is the result of blocked sialic acid expression in the glomeruli, but 
not related to direct toxic effects of Ac53FaxNeu5Ac. Yet, for the safe use in humans this prototype drug 
needs to be improved for intratumoral injections or specifically targeted to the tumor cells. Our group has 
recently encapsulated Ac53FaxNeu5Ac into tumor-targeting, biodegradable nanoparticles that allowed for 
the specific delivery of the sialic acid mimetic to melanoma cells in the blood stream (28).  
The potent and specific action of Ac53FaxNeu5Ac enabled us to block sialic acid expression in established 
tumors. We found that sialic acid blockade had a profound effect on the tumor microenvironment with a 
strong increase in NK cells, CD4+ and CD8+ T cells and reduced percentages of regulatory T cells as well 
as myeloid cells. As tumor sialic acids are involved in many processes, it is likely that the impact of sialic 
acid blockade on the tumor microenvironment is multifactorial (7,43). Our first mechanistic studies 
indicate that sialic acid blockade; i) induces pro-immune effects including enhanced dendritic cell 
maturation, and increased numbers and activation state of effector immune cells, especially CD8+ T cells; 
ii) decreases immune suppressive regulatory T cells and myeloid cells in the tumor; iii) facilitates tumor 
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cell killing by cytotoxic T cells and iv) potentiates other cancer immunotherapies. How sialic acid 
blockade results in these changes in the tumor microenvironment at the molecular level remains to be 
investigated. Possibly, injections with Ac53FaxNeu5Ac lead to the loss of tumor sialic acids that can 
otherwise interact with immune modulatory Siglecs on immune cells. Recently, Beatson and colleagues 
showed that tumor-derived and heavily sialylated Mucin 1 (MUC1) reprograms myeloid cells in their 
favor via the interaction with Siglec-9 (16). They showed that MUC1-Siglec-9 interactions stimulated the 
secretion of tumor-promoting factors (IL-6, M-CSF) from myeloid cells. Moreover, MUC1 binding to 
Siglec-9 induced the differentiation of monocytes to tumor-associated macrophages (TAMs). These data 
strongly support the concept that sialic acid interactions with Siglecs contribute to the formation of the 
immunosuppressive tumor microenvironment (7,8,10,20-22). In line with these findings, we have 
observed reduced numbers of myeloid cells in the tumors treated with the glycomimetics. Whether this 
effect is related to the inhibition of sialic acid-Siglec interactions remains to be investigated. The finding 
that sialic acid blockade still resulted in a survival benefit in tumor-bearing mice depleted of myeloid 
cells, emphasizes however a role of the inhibitor beyond modulation of myeloid cells. Next to altered 
Siglec ligand expression, also galectin binding to now uncapped glycans could influence tumor cell 
growth and progression (44).  
While sialic acid blockade can have a broad impact on cancer cells, our data strongly indicate that the 
increased cell death and growth inhibition, and even complete remission after Ac53FaxNeu5Ac treatment 
results from enhanced killing of tumor cells by cytotoxic T cells. This hypothesis is supported by several 
observations. First, depletion of CD8+ T cells from mice before and after tumor inoculation largely 
abrogated the anti-tumor effect of Ac53FaxNeu5Ac injections. Interestingly, also the depletion of NK cells 
prior to tumor inoculation abrogated the growth suppression mediated by the glycomimetic, whereas 
depletion of NK cells after tumor inoculation had no significant effect on Ac53FaxNeu5Ac-mediated 
growth suppression. These data indicate that NK cells limit B16-F10 take at an early stage after 
inoculation, but are less relevant for tumor control at a later stage. Second, we detected an increased 
number of CD8+ T cells present in tumors with sialic acid blockade. These T cells also showed higher 
expression of the degranulation marker CD107a on their membrane. Third, desialylated B16-F10OVA cells 
showed an increased susceptibility to killing by OVA-specific CD8+ T cells compared to control cells. 
Moreover, adoptive transfer of activated CD8+ OT-I T cells further increased tumor rejection in mice 
treated with Ac53FaxNeu5Ac. It has been suggested that hypersialylation of the Fas receptor protects tumor 
cells from Fas-mediated killing by cytotoxic T cells and that tumor sialic acids inhibit the release of 
cytotoxic granules from CD8+ T cells (45,46). Removal of negatively charged sialic acids could also 
influence the biophysical interaction between tumor cells and T cells for instance by affecting MHC I-T 
cell receptor interactions and subsequent signaling events (43,47). Accordingly, we observed increased 
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clustering between desialylated B16-F10 and CD8+ OT-I T cells compared to control tumor cells. These 
findings support the concept that sialic acid blockade advances tumor cell-T cell interactions. Further 
research is needed to unravel the mechanisms underlying the enhanced susceptibility of sialic acid-
depleted tumor cells to killing by cytotoxic T cells. Enhanced killing by CD8+ T cells, however, is likely 
to account for the strong tumor rejection observed when combining sialic acid blockade with adoptive T 
cell transfer. These findings suggest that the outcome of cellular immunotherapy (e.g. CAR T cell therapy) 
could be improved with sialic acid blockade in the tumor cells. It will also be interesting to investigate 
whether sialic acid blockade is able to potentiate cancer immunotherapy with immune checkpoint-
blocking antibodies like PD-1 and CTLA-4. 
Next to promoting adoptive T cell transfer therapy, we found that sialic acid blockade combined with CpG 
injections strongly reduced the growth of poorly immunogenic B16-F10WT cells. CpG injected at the tumor 
site has been shown to functionally mature dendritic cells and to induce robust anti-tumor CD8+ T cell 
responses (36,37,48). Indeed, we observed CpG-induced maturation of dendritic cells in the tumor 
microenvironment and interestingly, sialic acid blockade alone also resulted in increased maturation of 
dendritic cells. Combined CpG and Ac53FaxNeu5Ac co-injections even further enhanced dendritic cell 
maturation and activated CD8+ T cells numbers in the tumor. Likewise, tumor sialic acids inhibit dendritic 
cell activation by interacting with immune inhibitory Siglecs, and therefore suppress the initiation of anti-
tumor immune responses (7,49,50). Another explanation could be that Ac53FaxNeu5Ac has a direct effect 
on dendritic cells. We recently showed that blocking sialic acid expression in human monocyte-derived 
dendritic cells with Ac53FaxNeu5Ac lowered the threshold for activation by TLR ligands, most likely by 
preventing interactions with immune suppressive Siglecs (38). These findings thus imply that sialic acid 
blockade promotes anti-tumor immunity by facilitating dendritic cell maturation. 
 
We conclude that sialic acid blockade in established tumors is feasible by intratumoral injections of the 
fluorinated glycomimetic Ac53FaxNeu5Ac. Such injections significantly reduced melanoma as well as 
neuroblastoma growth and resulted even in remission in the immunogenic B16-F10OVA model. Sialic acid 
blockade created an immune permissive tumor microenvironment and rendered tumor cells vulnerable to 
killing by CD8+ T cells. Sialic acid blockade therefore potentiated the outcome of cellular immunotherapy 
with CD8+ T cells and strongly favored the induction of anti-tumor immunity after dendritic cell activation 
with CpG. These data support the current concept that tumor sialic acids have an immune modulatory role 
and participate in tumor immune evasion. Sialic acid blocking glycomimetics such as Ac53FaxNeu5Ac 
could therefore help to overcome the immune suppressive tumor microenvironment to permit strong tumor 
immune responses, alone or in combination with existing immunotherapies. 
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Figure Legends 
Figure 1 Intratumoral Ac53FaxNeu5Ac injections suppress tumor growth. 
A) Schematic representation of the experiment. B, C) Effect of intratumoral (i.t.) injections with sialic 
acid mimetics on B16-F10WT tumor growth. B16-F10WT tumor cells were inoculated subcutaneously (s.c.) 
and treated with PBS, 10 mg/kg or 30 mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac. Average B16-F10
WT tumor 
growth ± SEM in time (B) and corresponding Kaplan-Meier curves are shown (C) (n = 9-12). D) Kaplan-
Meier curves showing survival of mice with 9464D neuroblastoma treated with 10 mg/kg or 20 mg/kg 
sialic acid mimetics (n = 12). E, F) B16-F10OVA bearing mice were injected i.t. with PBS or 10 mg/kg 
sialic acid mimetics (n = 9-12). Average tumor volumes ± SEM of the treatment groups in time are shown 
(E) as well as corresponding Kaplan-Meier curves (F). G) Rechallenge of mice with B16-F10OVA cells 
after Ac53FaxNeu5Ac-induced remission of the initial primary tumor. Kaplan-Meier curves show tumor 
take in naïve age-matched control mice (n = 7) or rechallenged mice after Ac53FaxNeu5Ac therapy (n =9 ). 
 
Figure 2 Ac53FaxNeu5Ac blocks sialic acid expression and increases immune cell numbers in the tumor. 
A-K) B16-F10WT tumors treated for two weeks with PBS, 10 mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac were 
isolated to determine sialylation and immune cell infiltration (n = 6). A-D) Sialylation of tumor cells 
(CD45.2-). Representative histograms show binding of the lectins MALII, SNA-I and PNA that recognize 
α2,3-linked sialic acids, α2,6-linked sialic acids or terminal β-galactose, respectively (A). Bar diagrams 
show average binding percentages ± SEM of MALII (B), SNA (C) and PNA (D) to CD45.2
-
 cells. E-G) 
Representative images show stainings of tumor sections with MALII (E), SNA-I (F) or PNA (G). H) 
Mean percentage ± SEM viable, tumor-infiltrating CD45.2+ immune cells. I-K) Sialylation of immune 
cells (CD45.2+) in the tumor. Bar diagrams show average binding percentage ± SEM of the lectins MALII 
(I), SNA-I (J) and PNA (K) to tumor-infiltrating immune cells. 
 
Figure 3 Sialic acid blockade alters the immune cell composition of the tumor. 
A-K) Flow cytometry analysis of B16-F10WT tumors isolated from mice treated with PBS or 10 mg/kg 
sialic acid mimetics for two weeks. A-D) Analysis of viable, CD45.2+ NK cells (CD3- CD161+) (A), 
CD3+CD4+ T cells (B), CD3+CD8+ T cells (C), and CD4+CD25highFoxP3+ regulatory T cells (D). E-K) 
Dot plots showing mean percentages ± SEM of NK cells (E), CD4+ T cells (F), CD8+ T cells (G) 
regulatory T cells (H), CD45R+ B cells (I) CD11c+ dendritic cells (J) and CD11b+ myeloid cells (K) in the 
tumors of the different treatment groups (n = 6).  
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Figure 4 Depletion of CD8+ T cells abrogates the tumor suppressive effects of Ac53FaxNeu5Ac. 
A) Schematic representation of the experiment. B-D) Representative dot plots showing depletion of 
effector immune cell subsets. NK cells (B), CD4+ T cells (C), and CD8+ T cells (D) in blood three days 
following isotype (left) or depleting antibody (right) injection are shown. E) Kaplan-Meier curves show 
percentage survival of B16-F10WT tumor-bearing mice treated with PBS or 10 mg/kg Ac53FaxNeu5Ac in 
combination with isotype, CD4+ T cell or NK cell-depleting antibodies (n = 6). F) Kaplan-Meier curves 
showing percent survival of B16-F10WT tumor-bearing mice depleted from CD8+ T cells and treated with 
sialic acid mimetic or PBS (n = 12). 
 
Figure 5 Sialic acid blockade enhances tumor cell killing by cytotoxic T cells. 
A, B) In vitro killing of B16-F10WT and B16-10OVA target cells with blocked sialic acid expression by 
OVA-specific effector OT-I CD8+ T cells. A) Representative images show lysis of B16-F10OVA cells 
treated with PBS (upper row) or Ac53FaxNeu5Ac (lower row). B) Graph shows average killing percentage 
± SEM of sialic acid mimetic or sialidase-treated B16-F10WT and B16-F10OVA cells (n = 6). C, D) Effect 
of sialic acid blockade on B16-F10-OT-I CD8+ T cell clustering. PBSE-labeled B16-F10WT or B16-
F10OVA cells pre-treated with control or Ac53FaxNeu5Ac were incubated with CFSE-labeled OT-I CD8
+ T 
cells. Representative plots (C) and dot plot (D) showing average number of clusters ± SEM from three 
independent experiments. 
 
Figure 6 Intratumoral Ac53FaxNeu5Ac injections promote adoptive OT-I CD8
+ T cell transfer therapy.  
A-G) Combined effect of Ac53FaxNeu5Ac treatment and adoptive OT-I CD8
+ T cell transfer on B16-
F10OVA tumor growth. Schematic representation of the experiment (A). Bar diagrams show average 
percentage ± SEM of tumor-infiltrating CD45.1+ OT-I CD8+ T cells two days after adoptive transfer (B) 
and their expression of activation markers CD44 (C), CD69 (D) and CD107a (E) as average mean 
fluorescence intensity ± SEM (n = 3). Graph showing average tumor volume ± SEM (F) and Kaplan-
Meier curves showing percentage survival (G) of the different treatment groups (n = 12). The arrow 
indicates OT-I CD8+ T cell transfer. 
 
Figure 7 CpG immune adjuvant increases Ac53FaxNeu5Ac -mediated tumor growth suppression. 
A) Schematic representation of the experiment. B, C) B16-F10WT tumors were injected with PBS or 
Ac53FaxNeu5Ac three times a week and on day 14 and 21 post-inoculation CpG was co-injected. Graphs 
show average tumor volume ± SEM (B) and survival (C) of the different treatment groups. D-F) 
Infiltration and maturation status of CD11c+ dendritic cells. Bar diagrams show mean percentage tumor-
infiltrating dendritic cells ± SEM (D) and their expression of CD80 (E) and CD86 (F) as mean 
on July 27, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 27, 2018; DOI: 10.1158/0008-5472.CAN-17-3376 
Sialic Acid Blockade Boosts Anti-Tumor Immunity 
23 
 
fluorescence intensity ± SEM (n = 6). G-J) Number and activation status of CD8+ effector T cells in the 
tumor after treatment. Mean percentage ± SEM of CD8+ T cells is shown (G) as well as their expression 
of CD44 (H), CD69 (I) and CD107a (J) (n = 6). 
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